**Joint Conference on**
**Artemisinin production and market needs: Meeting Global Demand**
**Bangkok Thailand**
**25-26 June, 2007**

# FEEDBACK FORM

| **Was this conference useful to you?** | Yes | No |
|---|---|---|
| | 36 | 1 |

**Which session did you find particularly useful?**

- Individual presentations 29
- Plenary discussions 16
- Breakout group discussions 24

**Were the topics discussed in the breakout groups relevant?** Yes **18**

**What other topics would you have added?**

- Access and how it seems to be a major bottleneck for drug distribution
- How to avoid the boom to bust cycle for Artemisinin?
- How to get PQ for Artemisinin producers, just as the producers for CPI
- How to encourage farmers to plant more Artemisinin
- Mobile extraction units, storage and testing, Artemisinin bank, extraction and purification, marketing ACTs, substitute products in Africa
- Benefits of extending the shelf life of ACT from 2 to 3 years
- Efforts in co-ordinating and accessing databases
- Co-ordination of essential activities
- Acquisition of stability data, storage, extraction, PQ
- Distribution aspects
- Global ACT subsidy (principles were presented, but this is still a project, therefore nothing more could be said at the time of the meeting)
- Regulatory path
- Use plenary session to determine scope of breakout topics
- Purchase process for ACTs
- How to reduce time for pre-qualification
- Where is the money (Global fund)? How is it spent?
- ACT evolution and market (this was presented at the conference)
- Artemisinin market trends
- How to balance the demand and supply
- How to extend artemisinin shelf life from 2 to 3 years (artemisinin shelf life is actually 5 years, the 2-year shelf life concerns ACTs)
- Partnership between companies and research institutes

| **Do you think a follow up conference in two years is needed?** | Yes | No |
|---|---|---|
| | 33 | 1 |

Suggestion: next meeting in a major producing country – China or Vietnam

**What would you add to the content of a future meeting?**

- More time for discussions!
- Focus on pre-qualification for API and ACTs (presentation given by WHO)
- Regulatory issues
- Marketing (discussed in other break out sessions)
- How to reach poorest patients
- Scientific presentations on non-commercial problems
- Standardisation of plantation
- How to sustain the whole practice from plantation to allocation of finished formulation
- How to regulate activities
- How to protect all parties' interests
- How to get universally acceptable specifications for artemisinin (work in progress – included in presentations)
- Content should be guided by presenting issues at the same time (?)
- Different treatments and their evolution
- Prices established (minimum) (discussed in general discussion session)
- Global subsidy
- Frontier research discovery on various areas of Artemisinin such as: agriculture, chemical analysis, extraction, purification and other active constituents (largely covered in specific presentations)
- More science on background topics
- Too few scientists too many interested parties wanting to interact with them (this was one of the objectives of the meeting)
- New Semi Synthetic Artemisinins – desirable features of current Artemisinins (MMV presentation)
- Expertise in Artemisinin resistance
- Resistance needs to overcome – how? (ACT discussions)
- Social development, i.e. a financial foundation to help small holders to efficiently join the program with extraction units and an Artemisinin co-operative rather than an Artemisinin bank
- More precision on status of bio-synthetic Artemisinins (IOWH) & high-yield Artemisinin (York Uni.) (presentations but work in progress)
- Presentation on the market potential was vague. More realistic figures from WHO would be useful
- A technical session added, on a separate day
- Evaluation of ACTs
- Understand from key funders of ACTs the risk of undersupply of artemisinin raw material

**Are there any speakers you think we should invite?**

- Global Fund, UNICEFM GAVI, etc. India, RBM, ACTs manufacturers, China (?) Suppliers – Kunming Pharmaceutical Corp., Governor from African countries
- Big companies – Novartis and Sanofi-Aventis (invited to speak – S-A present)
- Reps of WHO Research institutes
- Donors
- A medical doctor from a big pharma
- African speakers and participants (EABL-Kenya and Bionexx, Madagascar spoke)
- Prof Coll-Seck (RBM)
- Jan Van Erps (Supply RBM) (was present at the conference)
- Inder Singh (Clinton Foundation) (gave a short presentation at the conference)
- Someone responsible for buying ACT on behalf of various public/private funds
- Novartis / Mepha (invited)
- A stakeholder analyst
- Clinton Foundation (see above)
- More Chinese participants – Li Guo Qiaos group in Guangzhou University of Trad. Chinese Medicine / Artepharm (over 10 participants from China)
- Experts in co-operatives to give a social trend to this program – (Anthony Ellman spoke)
- Reps from key funding agencies of ACT
- Speakers on technical aspects (see agenda)
- Derivative producers and ACT manufacturers
- Specialist on demand and supply from beginning of chain: farming, production of Artemisinin, API and ACTs

**Thank you for your responses. We will try to incorporate your feedback into any future Artemisinin production and market demand conference we hold.**